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1. Introduction
1.1. Classical renin-angiotensin system
The renin–angiotensin system (RAS) is an endocrine system that governs body fluid, electro‐
lyte balance and blood pressure. Within the classical RAS, angiotensinogen (AGT) secreted by
liver is enzymatically cleaved to angiotensin (ANG) I by kidney-derived renin. ANG I is,
hereafter, cleaved by angiotensin-converting enzyme (ACE) to generate the effector hormone
ANG II, which exerts various biological actions through its receptors, ANG II type 1 receptor
(AT1) and ANG II type 2 receptor (AT2). The initial reaction between the enzyme renin and
the substrate AGT is the rate-limiting step of the RAS [1].
As the RAS is a hormonal cascade that is thought to act as a master controller of blood pressure
and fluid balance within the body [2], the systematic RAS has been an important target of
antihypertensive medications. There are several groups of drugs in this category that affect
different parts of the RAS axis, including ACE inhibitors (ACEI) and angiotensin receptor
blockers (ARB), both of which are widely used for anti-hypertension treatment [3]. Addition‐
ally, Aliskiren, the first orally active direct renin inhibitor approved for clinical use, is a small
molecule competitive inhibitor that specifically inhibits the enzymatic activity of renin [4, 5],
consequently it could effectively suppress the rate-limiting step within RAS cascade to reduce
the production of ANG II. The recent evidences have shown the effective blood pressure
control of Aliskiren, generally well tolerated as monotherapy or in combination with other
antihypertensive drugs [3, 6].
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2. Tissue renin–angiotensin system
From an evolutionary point of view, it is cost-effective to have a common system to potentiate
and effect the actions of the regulating hormones. Interestingly, the RAS is also found in
primitive animals without a closed circulatory system, which indicates that the system is far
more than a mediator of vasoconstriction [7]. It is now evident that the components of RAS,
in addition to the classical pathway, are produced and acting locally in multiple tissues, a
concept known as tissue RAS [7]. The local effects of tissue RAS are diverse and depend on
the specific tissues involved.
The  functional  tissue  RAS  is  postulated  to  participate  in  various  physiological  and
pathological processes such as insulin secretion [8], glomerular sclerosis [9], renal inflamma‐
tion [10], atherosclerosis [11], cardiac hypertrophy [12], brain ischemia [13] and follicular
development and endometrial cancer in female reproductive tract [14]. A growing body of
studies has demonstrated that the diabetic complications,  such as cardiovascular disease
[15], nephropathy [16] and retinopathy [17], are caused by the high activity of tissue RAS
and the increased production of ANG II in local tissues, and the clinical practice has revealed
that these pathological alterations associated with diabetes were significantly improved in
response to the treatment with RAS inhibitors [15-17]. Additionally, hyperglycemia, obesity,
hypertension,  and cortisol,  well-known risk factors of  metabolic  disease,  are all  stimula‐
tors on tissue RAS, whereas glucagon-like peptide-1, vitamin D, and aerobic exercise could,
to some extent, prevent metabolic disease through inhibiting tissue RAS [7]. Thus, the factors
and drugs suppressing tissue RAS activity have potential in improving RAS-involved tissue
injuries.
Recent in vivo studies showed that the components of RAS, such as renin, ACE, and ANG II
receptors, were expressed in the local milieu of bone [1, 18-20], and in vitro study identified
the expression of ANG II receptors in primary osteoblasts derived from newborn mouse
calvaria [1], indicating the components of RAS are expressed locally in bone microenviron‐
ment. Our further animal studies demonstrated that the local RAS in bone was involved in
age-related osteoporosis of aging mice [21], and bone deteriorations of mice with either
obstructive nephropathy [22] or type 1 diabetes [23]. Other groups elucidated the involvement
of skeletal RAS in the process of fracture healing in a mouse femur fracture model [24], and
the steroid-induced osteonecrosis in rabbits [20] as well as the development of postmenopausal
osteoporosis in ovariectomized (OVX) animal models [25, 26] and glucocorticoid-induced
osteoporosis [19]. Therefore, it concludes that the local RAS exists in bone tissue and plays an
important role in local bone metabolism.
3. Action of angiotensin II on bone
ANG II has been postulated to be able to act upon the cells involved in bone metabolism
through receptors  located in  osteoblasts  and osteoclasts  or  regulate  blood flow in  bone
marrow capillaries. At the end of last century, the studies showed that ANG II stimulat‐
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ed DNA and collagen synthesis and decreased alkaline phosphatase (ALP) activity in bone
cell populations derived from calvariae of fetal rat [27] and newborn rat [28]. Similar effects
of ANG II were observed in osteoblastic ROS17/2.8 cells [29] and human adult bone cells
obtained  by  collagenase  digestion  from  trabecular  bone  [27].  The  clonal  cell  analysis,
autoradiographic studies, and receptor subtype analysis suggested that ANG II might be
intimately involved in the proliferation of the osteoblast-rich populations of cells through
the AT1 receptor [27, 28], which also plays one of the essential roles in bone metabolism
as a mechanoreceptor of osteoblasts [30].
When investigating the direct effects of ANG II on matured osteoblasts, the results revealed
that ANG II inhibited the expression of mRNA for osteocalcin, which is a protein that is
specifically expressed during maturation of osteoblastic cells, decreased the activity of ALP,
the number and the total area of mineralized nodules as well as reduced the accumulation of
calcium in cells and the matrix layer [31]. Besides, the ANG II-involved impairment of bone
formation may be attributed that it altered the expression of Cbfa1 by activating the cAMP
signaling pathway and subsequently reduced osteoblast number and osteoblastic function
[32]. SOST, which encodes sclerostin, is a secretory product of osteocytes that counters Wnt
signaling, thereby negatively regulates bone formation [33]. The AT1-involved inhibition on
bone formation was highly correlated with its regulation on downstream factor SOST, as the
decreased SOST expression in osteocytes was observed in AT1-deficient mice [34]. Further‐
more, the treatment with ANG II strikingly increased the expressions of matrix metallopro‐
teinase (MMP)-3 and-13 through MAPK signaling pathways via the AT1 in osteoblastic
ROS17/2.8 cells, suggesting that ANG II stimulated the degradation process that occurs during
extracellular matrix (ECM) turnover in osteoid by increasing the production of MMP-3 and-13
in osteoblasts [29]. Additionally, ANG II induced mitochondrial dysfunction and promoted
apoptosis via JNK signaling pathway in primary mouse calvaria osteoblast [35]. Taken
together, the target genes including Cbfa1, SOST, MMP-3 and MMP-13, and the signaling
pathways like MAPK and JNK are involved in the mediation of ANG II on osteoblastic function
and bone formation.
Osteoblast modulates osteoclast differentiation by producing both positive and negative
regulators, most notably receptor activator of NF-κB ligand (RANKL) and osteoprotegerin
(OPG), respectively [36]. Of note, it has been recently found that ANG II could induce the
differentiation of bone marrow mononuclear cells to multinuclear cells and the number of
multinuclear cells in osteoclasts as well as increase tartrate-resistant acid phosphatase (TRAP)-
positive multinuclear osteoclasts due to its stimulation on the expression of osteoclastogenesis-
supporting cytokine, RANKL in osteoblasts, leading to the activation of osteoclasts [1, 25],
whereas these effects were completely blocked by either ANG II type 1 receptor blockade
(olmesartan) or mitogen-activated protein kinase kinase inhibitors (U0126) [25]. Importantly,
ANG II itself had no capacity to induce osteoclast differentiation and did not potentiate
osteoclast formation triggered by RANKL, while it stimulated the formation of osteoclasts in
the co-culture system of primary osteoblasts and bone marrow macrophages in a dose-
dependent manner [1, 32]. Taken together, these results suggested that ANG II stimulates
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osteoclastogenesis by acting on osteoblastic cells (i.e., ‘the soil cells’), but not through a direct
action on hematopoietic ‘seed cells’ [1].
It was found that the TRAP activity and the TRAP-positive stained area were significantly
increased in the tibia of OVX rats with systemic administration of ANG II at a subpresser dose
(200 ng/kg/min), and the treatment with ANG II significantly induced the ovariectomy-
induced increase in urinary level of deoxypyridinoline [25]. The ratio of ALP to TRAP was
significantly decreased in the tibia of OVX rats upon to ANG II treatment. These results
suggested that ANG II accelerated the turnover of bone metabolism, which is similar to the
typical pattern in elderly postmenopausal women who are at high risk for osteoporosis [25].
Of importance, the bone density as assessed by double energy X ray absorptiometry (DEXA)
was significantly decreased in the tibia of OVX rats by ANG II. These results suggested that
ANG II directly accelerated estrogen deficiency-induced osteoporosis.
4. Interaction of AT1 and AT2 on bone
Previous studies have focused on the ANG II–AT1 interactions since these are the best
described and considered the most important. However, the system is complex and several
other components probably play significant roles as well [7]. Several publications raise the
possibility that AT1 and AT2 carry out negative cross-talk within fibroblasts and vascular
endothelial cells with respect to each other’s signaling pathways and responses [37]. This may
be of particular importance when the AT1 are pharmacologically blocked.
Asaba  et al. determined the relative contribution of the two receptors for transducing the
osteoclastogenesis-supporting  function  of  ANG  II  in  osteoblasts  by  knocking  down  the
expression of  each of  the receptors with siRNA in primary osteoblasts  in culture [1].  In
AT1-knockdown osteoblasts, the stimulatory effect of ANG II on osteoclast formation was
somewhat  enhanced.  In  AT2-knockdown  osteoblasts,  in  contrast,  the  osteoclastogenic
potential  was  markedly  attenuated  [1],  which  was  consistent  with  that  AT2  deficiency
increased  bone  mass  of  distal  metaphyseal  regions  of  femoral  in  mice  as  well  as  the
treatment with AT2 blocker PD123319 suppressed ANG II-induced increase in the num‐
ber of  osteoclasts  in organ cultures of  bone [18].  Asaba  et  al.’s  study suggested that  the
action  of  ANG  II  on  osteoblasts  in  terms  of  stimulating  osteoclastogenesis  was  mainly
mediated through the AT2 and AT1 might exert an inhibitory effect on AT2. These findings
in osteoblasts are consistent with the notion that the functions of AT1 and AT2 are in many
cases counter-regulatory to each other [7].  However,  they are contrary to the conclusion
that  AT2  is  the  protective  arm of  RAS and counterbalances  pathological  processes  and
enable recovery from disease [38]. Thus, further studies are needed to dissect the signal‐
ing pathways downstream of each receptor in osteoblasts.
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5. ACE inhibitors and osteoporosis
Osteoporosis, hypertension, diabetes are major chronic diseases in older subjects and the latter
two are well known to be high risk factors for osteoporosis. As ACE inhibitors are usually
prescribed for hypertension, cardiac failure, and diabetic nephropathy [23, 39], it is important
to know the prospective effects of ACEI on bones of these patients taking ACEI treatment.
Previously, most of clinical studies demonstrated that patients treated with ACEI showed an
increased bone mineral density (BMD) and a reduced fracture risk [40-45]. The menopausal
and hypertensive women who followed treatment with ACEI fosinopril did not present the
physiological loss of bone mass that affected to menopausal women without treatment [43].
A large case–control analysis carried out in the UK, suggested a possibly decreased fracture
risk associated with longer-term use of ACE inhibitors [40], and in an open prospective study
including 134 patients with low to moderate hypertension and stable BMD, the plasma calcium
and 25-hydroxyvitamin D levels were both increased in patients treated with the ACEI
quinapril [41]. It also significantly increased BMD of lumbar spine in female subjects with ACE
DD genotype, which could induce a higher level of ANG II [41]. The research group from Hong
Kong performed two large scale cohort studies which investigated the risk factors for osteo‐
porotic fractures in Hong Kong-dwelling elderly Chinese, and their data concluded that male
ACEI users had higher BMD at the total hip, female neck and lumbar spine than non-users.
Likewise, female ACEI users also had higher BMD than non-users, although only significant
at the femoral neck [42].
While, in the contrary to the above mentioned beneficial effects of ACEI on bone health, the
recent emerging evidences indicated that ACEI use did not change the rate and risk of fracture
[46], and even led to greater bone loss [39, 47, 48]. The same research group from Hong Kong
recently also stated that female continuous users of ACEI had increased bone loss both in total
hip and femur neck [47]. A large sample size study in American men also supported this theory
by showing that ACEI use was associated with increased bone loss [39], moreover, another
prospective study-a cohort study of atomic bomb survivors in Japan, demonstrated that ACEI
use was associated with increased bone loss of femoral neck in older Japanese [48].
Similarly in animal studies, the use of ACEI enalapril (10-20 mg/kg, i.g.) did not show positive
effects on bone function of OVX mice [49] or OVX spontaneously hypertensive rats (SHR) [50],
and the administration of enalapril (0.4 mg/kg, i.p.) in a dose recommended for the treatment
of hypertension did not cause significant changes in bone density, the ash and mineral content
or morphometric parameters of the femur in female Wistar rats [51]. Another ACEI moexipril,
when given alone at oral dose of 10 mg/kg, had no effect on the cancellous bone site in either
OVX or sham-operated rats and did not hamper the osteoprotective effects of 17beta-estradiol
[52]. Even though the treatment of Tsukuba hypertensive mouse with enalapril improved
osteoporosis [1] as well as the OVX rats in response to the treatment with ACEI captopril (1 or
5 mg/kg) showed the increased trabecular area of lumbar vertebrae (L4) and the improved
biomechanical properties by increasing L5 break stress and elastic modulus [26], our recent
published article elucidated that the treatment with captopril (10 mg/kg, i.g.) significantly
elevated serum level of TRAP 5b, and had a trend to decrease BMD of trabecular bone and
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damage micro-architecture of proximal tibial head and distal femoral end in type 1 diabetic
mice [23].
Based on the facts that ANG II locally in bone tissue has detrimental effects to bone function
and ACE is the major enzyme producing ANG II, it is surprising that ACEI could not improve
even accelerate bone loss in both humans and animals. Since the modest changes in ACE level
affect the levels of its substrates much more than its products, indicating that relatively small
changes in the levels of ACE affect kinin level more than ANG II level [53], a possible reason
comes from the regulation of ACE on kinin-kallikrein system within which bradykinin can
stimulate bone resorption and reduce BMD [47]. Another possible explanation we should
consider is that although short-term ACEI therapy was associated with decreased ANG II level,
there were some evidences that long-term ACE inhibition resulted in a return of ANG II
towards baseline level, so-called ‘ACE escape’ [47]. The complete mechanisms have not yet
been fully demonstrated. More research needs to be carried out to clarify the influence of the
ACEI treatment on bone health as this might be of clinical relevance when antihypertensive
therapy is initiated, particularly in hypertensive women who typically suffer from a concom‐
itant rapid onset of osteoporosis after menopause [52].
6. Angiotensin receptor blockers and osteoporosis
The clinical profiles of users of ACEI and ARB were very similar. In the USA, ARB was usually
prescribed when ACEI was not tolerated, thus explaining the smaller number of ARB users
[39] and limited human studies of ARB and BMD or fracture risk in the literatures [46]. The
completed studies on the affections of ARB on bone function in human and animals have
shown contradictory results.
The recent population-based, retrospective cohort study with propensity score-matching
using administrative databases in Ontario, Canada to examine the risk of osteoporosis-related
fractures in hypertensive elderly patients treated with ARBs versus ACEIs, showed that there
was no significant difference between the effects of ARBs and ACE inhibitors on hip and other
osteoporotic fractures [54]. A large cohort study on Medicare beneficiaries with a diagnosis of
hypertension initiating single-drug therapy for anti-hypertension treatment suggested the
increasingly protective effect of ARB on relative fracture risk over time [46]. While, the study
with large sample size of community-dwelling older adults from six different geographic
regions demonstrated that the use of ARBs did not have any significant overall effect on bone
loss in older men [39].
The contradictory results about the actions of ARBs on bone metabolism were also shown
among  animal  studies.  The  treatment  with  telmisartan,  olmesartan,  and  losartan,  could
reduce bone loss of OVX mice [49], attenuate the ovariectomy-induced decrease in BMD
[25], and increase bone strength, mass and trabecular connections of OVX rats femur [55,
56],  respectively.  Moreover,  telmisartan  partially  protected  from  thiazolidinedione-in‐
duced bone loss  by actively  blocking thiazolidinedione-induced anti-osteoblastic  activity
via maintaining PPARγ serine 112 phosphorylation [57], and promoted fracture healing in
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a mice model [58]. However, some studies reported ARBs did not cause significant changes
of bone properties in normal female rats [51], type 2 diabetic mice [57], OVX rats [59] or
orchiectomized rats [60]. Importantly, it was noted that in some animal models ARBs may
lead to more bone injuries [1, 61]. The treatment of transgenic Tsukuba hypertensive mouse
with losartan resulted in exacerbation of the low bone mass phenotype [1]. The study in
our  group demonstrated a  trend of  losartan to  promote  the  loss  of  bone mass  and the
deteriorations  of  trabecular  bone  micro-architecture  in  type  1  diabetic  mice  due  to  the
compensatory stimulation of bone RAS activation as shown by the up-regulation of renin
and ANG II expression in bone tissue [61].
7. Perspective
It has been argued that neither ACEIs nor ARBs completely block the RAS cascade due to the
disruption of the feedback inhibition of renin production [62]. The increase in renin activity
stimulates the conversion of ANG I and ultimately ANG II, which largely limits the efficacy
of RAS inhibition [63]. The increased renin can also act through the prorenin/renin receptor,
which may cause tissue damages independent of ANG II [64]. Thus, as compared to single
treatment with RAS inhibitors, whether combining renin inhibitor, like Aliskiren, with ARB
or ACEI could generate better therapeutic effects on tissue injuries, such as osteoporosis,
should be further clarified.
As discussed in this chapter, RAS locally plays a key role in the modulation of bone metabo‐
lism. However, over the past 10 years, several studies have presented evidences for the
existence of a new arm of the RAS, namely the ACE2/ANG-(1–7)/Mas axis [65]. The identifi‐
cation of the ACE homolog, ACE2 as a key ANG-(1–7)-forming enzyme, unravels the existence
of a distinct enzymatic pathway for the production of ANG-(1-7), which has a broad range of
effects in different organs and tissues that goes beyond its initially described cardiovascular
and renal actions [66]. This heptapeptide exerts its actions through binding to a G protein-
coupled receptor Mas, distinct from AT1 and AT2 [67]. It is now accepted that the ACE2/ANG-
(1–7)/Mas axis is able to counteract most of the deleterious actions of the ACE/ANG II/AT1
axis, especially in pathological conditions [68] such as cardiac dysfunction, increased blood
pressure, decreased baroreflex function, endothelial dysfunction, reduced reproductive
function, increased thrombogenesis [66]. Thus, how the cross-talk and the interaction between
the dual axis systems of RAS contribute to the maintainance of bone metabolism needs to be
further investigated and elucidated for better understanding the molecular mechanism of bone
metabolic diseases.
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